Metis Global Partners LLC Has $7.57 Million Stock Holdings in Amgen Inc. $AMGN

Metis Global Partners LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 8.2% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 27,096 shares of the medical research company’s stock after selling 2,411 shares during the period. Metis Global Partners LLC’s holdings in Amgen were worth $7,565,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in AMGN. Brighton Jones LLC boosted its position in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Abel Hall LLC bought a new stake in Amgen in the first quarter valued at about $232,000. Allworth Financial LP lifted its stake in Amgen by 4.9% in the first quarter. Allworth Financial LP now owns 36,755 shares of the medical research company’s stock valued at $11,451,000 after buying an additional 1,720 shares during the period. Alps Advisors Inc. lifted its stake in Amgen by 11.0% in the first quarter. Alps Advisors Inc. now owns 11,601 shares of the medical research company’s stock valued at $3,614,000 after buying an additional 1,152 shares during the period. Finally, Phillips Financial Management LLC bought a new position in Amgen during the first quarter worth about $247,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN stock opened at $320.20 on Friday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $335.88. The company’s fifty day simple moving average is $289.94 and its 200-day simple moving average is $288.50. The firm has a market cap of $172.38 billion, a PE ratio of 26.18, a P/E/G ratio of 2.61 and a beta of 0.45. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter last year, the firm earned $5.58 earnings per share. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 annualized dividend and a yield of 3.0%. Amgen’s dividend payout ratio is 73.57%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.76% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Morgan Stanley lowered their price target on Amgen from $333.00 to $329.00 and set an “equal weight” rating for the company in a research note on Wednesday. Piper Sandler restated an “overweight” rating on shares of Amgen in a report on Wednesday. Weiss Ratings upgraded shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Guggenheim boosted their price target on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Bank of America upped their price objective on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday, September 26th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $308.83.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.